Moreover, we show that GOT1 plays an important role in protecting CRC cells against OXPHOS inhibition, proposing GOT1 targeting as a potential strategy to improve the therapeutic efficacy of OXPHOS inhibitors in cancer treatment. Here, GOT1 is linked to colorectal carcinoma.